Formula & Concentration

Antihemophilic Factor (Recombinant)

Manufacturer

Takeda

Indications

The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes.2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL.3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient.

RECOMBINATE is not indicated in von Willebrand’s disease.

Product Options

Package Size NDC Presentation
220 IU – 400 IU 00944-2841-10 Vial
401 IU – 800 IU 00944-2842-10 Vial
801 IU – 1240 IU 00944-2843-10 Vial
1241-1800 IU 00944-2844-10 Vial
1801 – 2400 IU 00944-2845-10 Vial

Shelf Life & Storage

36 Months

RECOMBINATE can be refrigerated [2° – 8°C (36° – 46°F)] or stored at room temperature, not to exceed 30°C (86°F). Avoid freezing to prevent damage to the diluent vial. Do not use beyond the expiration date printed on the box.

Recombinate

Order Online

or call

800-304-3064

Can't find what you are looking for?

Please call us and we would love to help.

800-304-3064